Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiology | 23 | 2023 | 501 | 2.190 |
Why?
|
| Cardiovascular Diseases | 18 | 2022 | 1913 | 1.610 |
Why?
|
| American Heart Association | 18 | 2023 | 319 | 1.510 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2022 | 728 | 1.150 |
Why?
|
| Hyperlipidemias | 7 | 2022 | 175 | 1.020 |
Why?
|
| Research Report | 5 | 2021 | 75 | 0.850 |
Why?
|
| Anticholesteremic Agents | 8 | 2022 | 234 | 0.810 |
Why?
|
| Primary Prevention | 2 | 2021 | 167 | 0.790 |
Why?
|
| Chest Pain | 5 | 2021 | 124 | 0.750 |
Why?
|
| Practice Guidelines as Topic | 9 | 2021 | 1261 | 0.750 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 264 | 0.710 |
Why?
|
| Cholesterol | 5 | 2021 | 532 | 0.660 |
Why?
|
| Societies, Medical | 6 | 2021 | 687 | 0.620 |
Why?
|
| Aspirin | 1 | 2020 | 224 | 0.610 |
Why?
|
| Consensus | 13 | 2024 | 634 | 0.600 |
Why?
|
| Cholesterol, LDL | 7 | 2022 | 560 | 0.600 |
Why?
|
| Medication Adherence | 5 | 2022 | 400 | 0.550 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 256 | 0.520 |
Why?
|
| Secondary Prevention | 3 | 2021 | 216 | 0.510 |
Why?
|
| Ezetimibe | 4 | 2022 | 95 | 0.480 |
Why?
|
| Advisory Committees | 5 | 2019 | 151 | 0.480 |
Why?
|
| United States | 31 | 2024 | 10822 | 0.460 |
Why?
|
| Evidence-Based Medicine | 5 | 2021 | 631 | 0.430 |
Why?
|
| Hypercholesterolemia | 4 | 2018 | 227 | 0.430 |
Why?
|
| Dyslipidemias | 3 | 2024 | 228 | 0.390 |
Why?
|
| Algorithms | 4 | 2021 | 1614 | 0.370 |
Why?
|
| Atherosclerosis | 4 | 2022 | 849 | 0.350 |
Why?
|
| Coronary Artery Disease | 4 | 2021 | 760 | 0.350 |
Why?
|
| Diabetes Mellitus | 3 | 2022 | 859 | 0.330 |
Why?
|
| Awards and Prizes | 1 | 2010 | 64 | 0.330 |
Why?
|
| Hypertension | 3 | 2022 | 1288 | 0.330 |
Why?
|
| Coronary Disease | 2 | 2010 | 655 | 0.310 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 206 | 0.310 |
Why?
|
| Myocardial Infarction | 2 | 2010 | 1017 | 0.300 |
Why?
|
| Guideline Adherence | 2 | 2010 | 380 | 0.300 |
Why?
|
| Risk Reduction Behavior | 4 | 2021 | 140 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2024 | 1251 | 0.280 |
Why?
|
| Heart Valve Diseases | 2 | 2021 | 169 | 0.280 |
Why?
|
| Humans | 50 | 2025 | 124502 | 0.260 |
Why?
|
| Registries | 3 | 2021 | 1419 | 0.250 |
Why?
|
| Medication Therapy Management | 3 | 2018 | 25 | 0.220 |
Why?
|
| Hypoglycemic Agents | 2 | 2024 | 441 | 0.220 |
Why?
|
| Hypolipidemic Agents | 2 | 2008 | 179 | 0.210 |
Why?
|
| Aged | 12 | 2025 | 19560 | 0.210 |
Why?
|
| Aortic Diseases | 2 | 2023 | 199 | 0.210 |
Why?
|
| Risk Factors | 9 | 2021 | 10182 | 0.200 |
Why?
|
| Risk Assessment | 7 | 2021 | 3394 | 0.190 |
Why?
|
| Cardiovascular System | 1 | 2022 | 106 | 0.190 |
Why?
|
| Military Medicine | 1 | 2021 | 49 | 0.180 |
Why?
|
| Diet Therapy | 1 | 2021 | 41 | 0.180 |
Why?
|
| Heart Valves | 1 | 2021 | 52 | 0.180 |
Why?
|
| Nutrition Policy | 1 | 2021 | 100 | 0.180 |
Why?
|
| Expert Testimony | 1 | 2020 | 37 | 0.170 |
Why?
|
| Lipids | 2 | 2022 | 512 | 0.170 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 102 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 123 | 0.160 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2021 | 157 | 0.160 |
Why?
|
| Deprescriptions | 1 | 2019 | 12 | 0.160 |
Why?
|
| Inappropriate Prescribing | 1 | 2019 | 41 | 0.160 |
Why?
|
| Aging | 1 | 2025 | 1185 | 0.150 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 1088 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2020 | 464 | 0.130 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2021 | 440 | 0.130 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2016 | 39 | 0.130 |
Why?
|
| Cholesterol, HDL | 2 | 2010 | 350 | 0.130 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2015 | 49 | 0.120 |
Why?
|
| Lower Extremity | 1 | 2017 | 186 | 0.120 |
Why?
|
| Pharmacists | 1 | 2015 | 84 | 0.120 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2015 | 108 | 0.110 |
Why?
|
| Anticoagulants | 2 | 2015 | 588 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2024 | 16270 | 0.110 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2016 | 109 | 0.110 |
Why?
|
| Disease Management | 2 | 2015 | 521 | 0.110 |
Why?
|
| Female | 11 | 2024 | 66333 | 0.110 |
Why?
|
| Coronary Angiography | 1 | 2016 | 427 | 0.110 |
Why?
|
| Middle Aged | 6 | 2024 | 26526 | 0.110 |
Why?
|
| Biomarkers | 5 | 2021 | 2990 | 0.110 |
Why?
|
| Peripheral Arterial Disease | 1 | 2017 | 284 | 0.110 |
Why?
|
| Health Policy | 1 | 2015 | 212 | 0.100 |
Why?
|
| Postal Service | 1 | 1992 | 9 | 0.100 |
Why?
|
| Consumer Behavior | 1 | 1992 | 39 | 0.100 |
Why?
|
| Pharmaceutical Services | 1 | 1992 | 35 | 0.100 |
Why?
|
| Aortic Valve | 1 | 2015 | 442 | 0.100 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2016 | 237 | 0.100 |
Why?
|
| Heart Failure | 1 | 2025 | 2276 | 0.090 |
Why?
|
| Observational Studies as Topic | 2 | 2021 | 88 | 0.090 |
Why?
|
| Managed Care Programs | 2 | 2022 | 61 | 0.090 |
Why?
|
| Global Health | 2 | 2019 | 558 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2015 | 547 | 0.090 |
Why?
|
| Treatment Outcome | 7 | 2021 | 12322 | 0.090 |
Why?
|
| Achievement | 1 | 2010 | 31 | 0.090 |
Why?
|
| Adult | 5 | 2024 | 29407 | 0.090 |
Why?
|
| Health Personnel | 1 | 2015 | 505 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 6487 | 0.080 |
Why?
|
| Patient Care | 1 | 2010 | 99 | 0.080 |
Why?
|
| Male | 7 | 2024 | 61062 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2010 | 286 | 0.080 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 267 | 0.080 |
Why?
|
| Medicare | 2 | 2022 | 424 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2010 | 447 | 0.080 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 644 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 1 | 2010 | 227 | 0.070 |
Why?
|
| Hospitals | 1 | 2010 | 398 | 0.070 |
Why?
|
| Triglycerides | 1 | 2010 | 565 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 1106 | 0.070 |
Why?
|
| Comorbidity | 2 | 2021 | 1527 | 0.060 |
Why?
|
| Cholesterol, VLDL | 1 | 2004 | 15 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2010 | 636 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 2127 | 0.060 |
Why?
|
| Multimorbidity | 1 | 2022 | 20 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2025 | 477 | 0.050 |
Why?
|
| Medicaid | 1 | 2024 | 243 | 0.050 |
Why?
|
| United States Department of Defense | 1 | 2021 | 10 | 0.050 |
Why?
|
| Protective Factors | 1 | 2021 | 85 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 52 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2024 | 1158 | 0.050 |
Why?
|
| Pregnancy | 2 | 2024 | 7170 | 0.050 |
Why?
|
| Patient Care Management | 1 | 2021 | 67 | 0.040 |
Why?
|
| Committee Membership | 1 | 2020 | 4 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2010 | 4749 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2024 | 1129 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 169 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1178 | 0.040 |
Why?
|
| Aorta | 1 | 2023 | 538 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2000 | 105 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2021 | 443 | 0.040 |
Why?
|
| Angina, Unstable | 1 | 1998 | 52 | 0.040 |
Why?
|
| Drug Prescriptions | 2 | 2008 | 221 | 0.040 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2000 | 174 | 0.040 |
Why?
|
| Thromboembolism | 1 | 1998 | 90 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2018 | 77 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2021 | 686 | 0.040 |
Why?
|
| Sequestering Agents | 1 | 2017 | 2 | 0.040 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 301 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 351 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2021 | 671 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2017 | 57 | 0.030 |
Why?
|
| Heparin | 1 | 1998 | 228 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2021 | 850 | 0.030 |
Why?
|
| Drug-Eluting Stents | 1 | 2016 | 55 | 0.030 |
Why?
|
| Classification | 1 | 2015 | 18 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 578 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2015 | 113 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 220 | 0.030 |
Why?
|
| Morbidity | 1 | 2014 | 244 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 290 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3426 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 3094 | 0.020 |
Why?
|
| Time Factors | 1 | 2021 | 6285 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 426 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 582 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2006 | 197 | 0.010 |
Why?
|
| Prognosis | 1 | 2014 | 4572 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2008 | 496 | 0.010 |
Why?
|
| Adolescent | 1 | 2021 | 19303 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 1807 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 1992 | 3725 | 0.010 |
Why?
|
| Partial Thromboplastin Time | 1 | 1998 | 46 | 0.010 |
Why?
|
| Medical Records | 1 | 1998 | 191 | 0.010 |
Why?
|
| Hospital Costs | 1 | 1998 | 179 | 0.010 |
Why?
|
| Body Weight | 1 | 1998 | 1004 | 0.010 |
Why?
|
| Length of Stay | 1 | 1998 | 1309 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 1998 | 2898 | 0.010 |
Why?
|
| Texas | 1 | 1998 | 3588 | 0.010 |
Why?
|